Table_4_miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma.xlsx
MicroRNAs are a group of endogenous small non-coding RNAs commonly dysregulated in tumorigenesis, including glioblastoma (GBM), the most malignant brain tumor with rapid proliferation, diffuse invasion, and therapeutic resistance. Accumulating evidence has manifested that miR-1258 exerts an inhibitory role in many human cancers. However, the expression pattern of miR-1258 and its potential function in GBM tumorigenesis remain unclear. In this study, we reported that miR-1258 expression decreased with the ascending pathological grade of glioma, which indicated an unfavorable prognosis of patients. Functional assays revealed an inhibitory effect of miR-1258 on malignant proliferation, therapeutic resistance, migration, and invasion of GBM in vitro. Moreover, xenograft models also suggested a repression effect of miR-1258 on gliomagenesis. Mechanistically, miR-1258 directly targeted E2F1 in 3’-untranslated regions and attenuated E2F1-mediated downstream gene PCNA and MMP2 transcriptions. Furthermore, restoration of E2F1 expression in GBM cells effectively rescued the tumor-suppressive effect of miR-1258. Our studies illustrated that miR-1258 functioned as a tumor suppressor in GBM by directly targeting E2F1, subsequently inhibiting PCNA and MMP2 transcriptions, which contributed to new potential targets for GBM therapy and other E2F1-driven cancers.
History
References
- https://doi.org//10.3322/caac.21613
- https://doi.org//10.1038/s41568-020-00306-0
- https://doi.org//10.3390/cancers11010017
- https://doi.org//10.1038/s41388-020-1307-3
- https://doi.org//10.1016/j.bbrc.2019.01.139
- https://doi.org//10.1111/cpr.12505
- https://doi.org//10.1001/jamaoncol.2016.6020
- https://doi.org//10.3390/biomedicines7040090
- https://doi.org//10.1093/neuonc/5.2.79
- https://doi.org//10.1158/1078-0432.Ccr-14-2680
- https://doi.org//10.4161/23723548.2014.970480
- https://doi.org//10.1038/nrc2718
- https://doi.org//10.1158/0008-5472.Can-11-2196
- https://doi.org//10.1158/0008-5472.Can-11-2575
- https://doi.org//10.1016/j.tcb.2020.05.002
- https://doi.org//10.1093/neuonc/noy037
- https://doi.org//10.1007/bf00227728
- https://doi.org//10.3321/j.issn%3A1000-467X.2003.10.016
- https://doi.org//10.1215/15228517-2008-001
- https://doi.org//10.1371/journal.pone.0172234
- https://doi.org//10.1002/advs.201902971
- https://doi.org//10.1136/gutjnl-2019-318279
- https://doi.org//10.1182/blood-2016-10-697698
- https://doi.org//10.1038/nrgastro.2017.169
- https://doi.org//10.1016/j.semcancer.2020.04.001
- https://doi.org//10.1111/bjh.16517
- https://doi.org//10.1038/cr.2008.282
- https://doi.org//10.1158/0008-5472.Can-15-3240
- https://doi.org//10.18632/oncotarget.8030
- https://doi.org//10.1007/s11060-018-2819-3
- https://doi.org//10.1186/s12885-019-6480-9
- https://doi.org//10.1016/j.canlet.2019.03.011
- https://doi.org//10.1016/j.biopha.2018.11.074
- https://doi.org//10.1038/ncb0703-587
- https://doi.org//10.1038/sj.cdd.4401324
- https://doi.org//10.1186/s12943-020-01183-9
- https://doi.org//10.1093/neuonc/noy207
- https://doi.org//10.1038/s41419-020-02855-6
- https://doi.org//10.7150/thno.19904
- https://doi.org//10.1002/jcb.29453
- https://doi.org//10.1016/j.yexmp.2020.104368
- https://doi.org//10.1002/path.1711620403
- https://doi.org//10.1038/nrc3726
- https://doi.org//10.1016/s0014-5793%2803%2900485-x
- https://doi.org//10.1158/1538-7445.Am2011-268